Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099

Valérie Journot; Geneviève Chêne; Nathalie De Castro; Corinne Rancinan; Jill-Patrice Cassuto; Christian Allard; Jean-Louis Vildé; Alain Sobel; Michel Garré; Jean-Michel Molina; and ALIZE Study Group

首页> 外文期刊>Clinical Infectious Diseases >Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099

【24h】

Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099

机译：依法韦仑的使用与抑郁症的较高风险无关：临床随机试验ALIZE-ANRS 099的一项子研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. Efavirenz (EFV) is a highly active antiretroviral drug, use of which is associated with frequent (although transient) neurosensorial adverse reactions. Whether the use of EFV is associated with the risk of depression or suicide remains controversial.

机译：背景。 Efavirenz（EFV）是一种高活性的抗逆转录病毒药物，其使用与频繁（尽管短暂）的神经感觉不良反应相关。 EFV的使用是否与抑郁或自杀风险相关仍存在争议。

著录项

来源
《Clinical Infectious Diseases》 |2006年第12期|1790-1799|共10页
作者
Valérie Journot; Geneviève Chêne; Nathalie De Castro; Corinne Rancinan; Jill-Patrice Cassuto; Christian Allard; Jean-Louis Vildé; Alain Sobel; Michel Garré; Jean-Michel Molina; and ALIZE Study Group;
展开▼
作者单位

INSERM U593 Bordeaux;

Assistance Publique—Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis Department of Infectious Diseases and Université Paris 7 Paris;

Faculté de Medécine Department of Infectious and Tropical Diseases Paris;

Faculté Xavier Bichat Department of Infectious and Tropical Diseases Paris;

Centre Hospitalier Universitaire de Nice Hôpital de l'Archet 1 Department of Hematology Nice;

Centre Hospitalier Général de Meaux Department of Hematology Meaux;

AP-HP Hôpital Henri Mondor Department of Clinical Immunology Créteil;

Hôpital de la Cavale Blanche Department of Infectious and Tropical Diseases Brest France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. [J] . Grace A McComsey, Eric S Daar, MaryAnn ORiordan, The Journal of Infectious Diseases . 2013,第4期

机译：接受阿扎那韦-利托那韦或依非韦伦随机分配至阿巴卡韦-拉米夫定或替诺福韦DF-曲美他滨的受试者体内脂肪线粒体DNA和功能的变化：艾滋病临床试验小组研究A5224s，A5202的子研究。
2. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. [J] . Grace A McComsey, Eric S Daar, MaryAnn ORiordan, The Journal of Infectious Diseases . 2013,第4期

机译：用Atazanavir-Ritonavir或Efaviravir或Efaviravir或Efaviravir或enfaviravir-emtricticabine随机化的脂肪线粒体DNA的变化及其在受试者中的功能：艾滋病临床试验组研究A5224S，归档为A5202。
3. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. [J] . McComsey GA, Kitch D, Daar ES, The Journal of Infectious Diseases . 2011,第12期

机译：初次接受抗逆转录病毒治疗的人的骨矿物质密度和骨折随机接受阿巴卡韦-拉米夫定或替诺福韦二吡呋酯富马酸-恩曲他滨联合依非韦伦或阿扎那韦-利托那韦：艾滋病临床试验组A5224s，是ACTG A5202的一项子研究。
4. Effectiveness of biofeedback, active exercise and passive treatment on work-related musculoskeletal disorders: preliminary results of a randomized clinical trial [C] . Ma Chao, Szeto Grace, Yan Tiebin 17th World Congress on Ergonomics(第十七届国际人类工效学大会）论文集 . 2009

机译：生物反馈，主动运动和被动治疗对与工作有关的肌肉骨骼疾病的有效性：一项随机临床试验的初步结果
5. A Randomized, Double-Blind, Placebo-Controlled Crossover Trial Evaluating the Effect of Intranasal Insulin on Cognition and Emotional Processing in Individuals with Treatment-Resistant Major Depressive Disorder. [D] . Cha, Danielle Soh-Young. 2016

机译：一项随机，双盲，安慰剂对照的交叉试验评估了鼻内胰岛素对难治性重度抑郁症患者认知和情绪加工的影响。
6. Editors Choice: Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s a Substudy of ACTG A5202 [O] . Grace A. McComsey, Douglas Kitch, Eric S. Daar, -1

机译：编辑选择：抗逆转录病毒纯种患者的骨矿物质密度和骨折随机接受阿巴卡韦-拉米夫定或替诺福韦替诺福韦酯富马酸酯-依米他滨治疗依法韦仑或阿扎那韦-利托那韦：AIDS临床试验A5224sACTG A520的子研究
7. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 [O] . McComsey, Grace A., Kitch, Douglas, Daar, Eric S., 2011

机译：抗逆转录病毒天真患者的骨矿物质密度和骨折，随机接受阿巴卡韦-拉米夫定或替诺福韦地替莫韦酯富马酸酯-依米他滨与依非韦伦或阿扎那韦-利托那韦的联合治疗：AIDS临床试验组A5224s，是ACTG A5202的一项子研究

Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099

摘要

著录项

相似文献

相关主题

期刊订阅